MedPath
Found 120 clinical trials|View Analysis
Sort by:

PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients

Phase 3
Not yet recruiting
Conditions
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
Interventions
Radiation: radiotherapy
Drug: Dostarlimab
Biological: Biological study on circulating tumor DNA (optional for the patient)
First Posted Date
2025-01-07
Last Posted Date
2025-01-07
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Target Recruit Count
68
Registration Number
NCT06762405
Locations
🇫🇷

CHU Dijon Bourgogne, Dijon, France

Asian Watch-and-Wait Database (AWWD)

Recruiting
Conditions
Rectal Adenocarcinoma
Rectal Cancer
First Posted Date
2024-10-08
Last Posted Date
2024-11-20
Lead Sponsor
Tata Memorial Centre
Target Recruit Count
337
Registration Number
NCT06631443
Locations
🇮🇳

Tata Memorial Centre, Mumbai, Maharashtra, India

First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers

Phase 1
Recruiting
Conditions
Advanced Solid Tumors
Breast Cancer Recurrent
Colorectal Cancer Metastatic
Colon Cancer
Rectal Adenocarcinoma
Endometrial Cancer
Interventions
Drug: ATX-559
First Posted Date
2024-10-03
Last Posted Date
2024-12-31
Lead Sponsor
Accent Therapeutics
Target Recruit Count
100
Registration Number
NCT06625515
Locations
🇺🇸

SCRI Oncology Partners, Nashville, Tennessee, United States

🇺🇸

NEXT Oncology, San Antonio, Texas, United States

Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer

Phase 2
Withdrawn
Conditions
Stage IV Colorectal Cancer AJCC v8
Advanced Colon Adenocarcinoma
Stage IV Colon Cancer AJCC v8
Advanced Colorectal Adenocarcinoma
Metastatic Colorectal Adenocarcinoma
Advanced Rectal Adenocarcinoma
Metastatic Colon Adenocarcinoma
Stage III Colon Cancer AJCC v8
Stage IV Rectal Cancer AJCC v8
Metastatic Rectal Adenocarcinoma
Interventions
Biological: Balstilimab
Procedure: Biopsy
Procedure: Biospecimen Collection
Biological: Botensilimab
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Regorafenib
First Posted Date
2024-08-28
Last Posted Date
2024-11-21
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
84
Registration Number
NCT06575725
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

A Phase II Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy

Phase 2
Recruiting
Conditions
Rectal Adenocarcinoma
Interventions
First Posted Date
2024-08-26
Last Posted Date
2024-08-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
60
Registration Number
NCT06569368
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Effect of Pelvic Rehabilitation After Low Anterior Resection for Cancer Rectum. - A Randomised Controlled Trial

Not Applicable
Not yet recruiting
Conditions
Rectum Neoplasm
Rectal Neoplasms
Rectal Cancer
Fecal Incontinence
Low Anterior Resection Syndrome
Bowel Dysfunction
Rectal Adenocarcinoma
Interventions
Behavioral: Conventional group
Behavioral: Pelvic Floor Physiotherapy (PFR)
First Posted Date
2024-07-29
Last Posted Date
2024-07-29
Lead Sponsor
GEM Hospital & Research Center
Target Recruit Count
77
Registration Number
NCT06524362
Locations
🇮🇳

GEM Hospital & Research Center, Coimbatore, Tamil Nadu, India

Evaluation Contact X-ray Brachytherapy for Rectal Preservation in Intermediate Substage Rectal Adenocarcinoma

Phase 3
Recruiting
Conditions
Adult With Intermediate Low or Mid Rectal Adenocarcinoma
Interventions
Radiation: contact X-ray brachytherapy (CXB)
First Posted Date
2024-05-07
Last Posted Date
2025-01-01
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
212
Registration Number
NCT06402864
Locations
🇫🇷

Institut Gustave Roussy, Villejuif, France

Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer

Not Applicable
Recruiting
Conditions
Rectal Adenocarcinoma
Rectal Cancer
Interventions
Procedure: Nonoperative surveillance
First Posted Date
2024-03-25
Last Posted Date
2024-10-09
Lead Sponsor
Tampere University Hospital
Target Recruit Count
200
Registration Number
NCT06328361
Locations
🇪🇪

East Tallinn Central Hospital, Tallinn, Estonia

🇪🇪

North Estonia Medical Centre, Tallin, Estonia

🇪🇪

West Tallinn Central Hospital, Tallin, Estonia

and more 10 locations

The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma

Phase 2
Recruiting
Conditions
Rectal Adenocarcinoma
Interventions
Drug: Adebrelimab
Drug: Oxaliplatin
Drug: Capecitabine
Radiation: Short-course Radiation
Procedure: Biopsy
First Posted Date
2024-02-20
Last Posted Date
2024-02-20
Lead Sponsor
Sir Run Run Shaw Hospital
Target Recruit Count
30
Registration Number
NCT06266832
Locations
🇨🇳

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Multicenter Observational Study Taulí-T1 Classification for the Management of pT1 Rectal Adenocarcinoma

Recruiting
Conditions
Rectal Cancer Stage I
First Posted Date
2024-01-23
Last Posted Date
2024-01-23
Lead Sponsor
Corporacion Parc Tauli
Target Recruit Count
317
Registration Number
NCT06218108
Locations
🇪🇸

Hospital Universitario Parc Tauli de Sabadell, Sabadell, Barcelona, Spain

© Copyright 2025. All Rights Reserved by MedPath